Literature DB >> 8495412

Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats.

C V Rao1, A Rivenson, M Katiwalla, G J Kelloff, B S Reddy.   

Abstract

Oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione], a substituted 1,2-dithiole-3-thione, protects against the acute and chronic toxicities of many xenobiotics and prevents chemically induced carcinogenicity in several target organs of rodents. The effects of dietary oltipraz, fed during the initiation and postinitiation stages, on azoxymethane-induced colon carcinogenesis and on the levels of several detoxifying enzymes, namely, glutathione S-transferase, NAD(P)H:quinone reductase, and UDP-glucurinyl transferase activities, were studied in male F344 rats. At 5 weeks of age, groups of animals were fed the control diet (modified AIN-76A diet) or a diet containing 200 ppm (40% maximum tolerated dose) of oltipraz. At 7 weeks of age, all animals except those in the vehicle (normal saline solution)-treated groups were given two weekly s.c. injections of azoxymethane at a dose of 15 mg/kg body weight. Three days after the second injection of azoxymethane, the groups of animals fed the oltipraz diet were transferred to the control diet (termed the initiation period) and the groups of animals receiving the control diet were transferred to the oltipraz diet (termed the postinitiation period). All groups were continued on this regimen until the termination of the experiment at 52 weeks after the carcinogen treatment. Intestinal tumors were evaluated histopathologically using routine procedures. Liver, colonic mucosa, and tumors were analyzed for glutathione S-transferase, NAD(P)H:quinone reductase, and UDP-glucurinyl transferase activities. The results indicate that oltipraz administered during the initiation stage significantly inhibited the incidence and multiplicity of invasive adenocarcinomas of the colon (P < 0.001), as well as the multiplicity of invasive and noninvasive adenocarcinomas (P < 0.01). Feeding of oltipraz during the postinitiation phase completely suppressed the formation of invasive adenocarcinomas (P < 0.0001) and significantly inhibited the formation of noninvasive and total adenocarcinomas, as well as the multiplicity (tumors/tumor-bearing animal, P < 0.001). Furthermore, oltipraz significantly suppressed the tumor volume when administered during the initiation phase (> 80%) or the postinitiation (> 93%) phase. Animals fed the oltipraz diet during the postinitiation stage showed increased levels of glutathione S-transferase, NAD(P)H:quinone reductase, and UDP-glucurinyl transferase activities (2-6-fold). Although the precise mechanism by which oltipraz inhibits colon tumor initiation and/or promotion remains to be elucidated, it is likely that the effect during the initiation stage may be due to an alteration of carcinogen metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495412

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

Authors:  Denis E Corpet; Sylviane Taché
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

2.  Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis.

Authors:  Hiroshi Y Yamada; Yixin Yao; Xiaoxing Wang; Yuting Zhang; Ying Huang; Wei Dai; Chinthalapally V Rao
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

Review 3.  Targeting NRF2 signaling for cancer chemoprevention.

Authors:  Mi-Kyoung Kwak; Thomas W Kensler
Journal:  Toxicol Appl Pharmacol       Date:  2009-09-02       Impact factor: 4.219

Review 4.  Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway.

Authors:  S Preethi; K Arthiga; Amit B Patil; Asha Spandana; Vikas Jain
Journal:  Mol Biol Rep       Date:  2022-03-28       Impact factor: 2.742

5.  Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention.

Authors:  Murugesan Velayutham; Rajendra B Muthukumaran; Joe Z Sostaric; John McCraken; James C Fishbein; Jay L Zweier
Journal:  Free Radic Biol Med       Date:  2007-07-06       Impact factor: 7.376

Review 6.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

7.  Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.

Authors:  Chinthalapally V Rao; Vernon E Steele; Malisetty V Swamy; Jagan M R Patlolla; Suresh Guruswamy; Levy Kopelovich
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

8.  Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice.

Authors:  Tamao Nishihara; Miyako Baba; Morihiro Matsuda; Masahiro Inoue; Yasuko Nishizawa; Atsunori Fukuhara; Hiroshi Araki; Shinji Kihara; Tohru Funahashi; Shinji Tamura; Norio Hayashi; Hiroyasu Iishi; Iichiro Shimomura
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

Review 9.  Dithiolethiones for cancer chemoprevention: where do we stand?

Authors:  Yuesheng Zhang; Rex Munday
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

Review 10.  The emerging role of the Nrf2-Keap1 signaling pathway in cancer.

Authors:  Melba C Jaramillo; Donna D Zhang
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.